Dectin-1 Binding to Annexins on Apoptotic Cells Induces Peripheral Immune Tolerance via NADPH Oxidase-2.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
24 12 2019
Historique:
received: 19 03 2019
revised: 18 07 2019
accepted: 20 11 2019
entrez: 26 12 2019
pubmed: 26 12 2019
medline: 29 9 2020
Statut: ppublish

Résumé

Uptake of apoptotic cells (ACs) by dendritic cells (DCs) and induction of a tolerogenic DC phenotype is an important mechanism for establishing peripheral tolerance to self-antigens. The receptors involved and underlying signaling pathways are not fully understood. Here, we identify Dectin-1 as a crucial tolerogenic receptor binding with nanomolar affinity to the core domain of several annexins (annexin A1, A5, and A13) exposed on ACs. Annexins bind to Dectin-1 on a site distinct from the interaction site of pathogen-derived β-glucans. Subsequent tolerogenic signaling induces selective phosphorylation of spleen tyrosine kinase (SYK), causing activation of NADPH oxidase-2 and moderate production of reactive oxygen species. Thus, mice deficient for Dectin-1 develop autoimmune pathologies (autoantibodies and splenomegaly) and generate stronger immune responses (cytotoxic T cells) against ACs. Our data describe an important immunological checkpoint system and provide a link between immunosuppressive signals of ACs and maintenance of peripheral immune tolerance.

Identifiants

pubmed: 31875551
pii: S2211-1247(19)31577-3
doi: 10.1016/j.celrep.2019.11.086
pii:
doi:

Substances chimiques

Annexins 0
Antigens 0
Lectins, C-Type 0
NF-kappa B 0
Reactive Oxygen Species 0
beta-Glucans 0
dectin 1 0
NADPH Oxidase 2 EC 1.6.3.-
Syk Kinase EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4435-4446.e9

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Kevin Bode (K)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany; Faculty of Biosciences, Ruprecht Karls University Heidelberg, 69120 Heidelberg, Germany.

Fatmire Bujupi (F)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany; Faculty of Biosciences, Ruprecht Karls University Heidelberg, 69120 Heidelberg, Germany.

Corinna Link (C)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany; Faculty of Biosciences, Ruprecht Karls University Heidelberg, 69120 Heidelberg, Germany.

Tobias Hein (T)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany; Faculty of Biosciences, Ruprecht Karls University Heidelberg, 69120 Heidelberg, Germany.

Stephanie Zimmermann (S)

Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14476 Potsdam, Germany; Department of Biology, Chemistry and Pharmacy, Free University Berlin, 14195 Berlin, Germany.

Diluka Peiris (D)

Attana AB, Greta Arwidssons v. 21, 11419 Stockholm, Sweden.

Vincent Jaquet (V)

Department of Pathology and Immunology, University of Geneva, 1211 Geneva, Switzerland.

Bernd Lepenies (B)

Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, 14476 Potsdam, Germany; Immunology Unit and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.

Heiko Weyd (H)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany. Electronic address: h.weyd@dkfz-heidelberg.de.

Peter H Krammer (PH)

Division of Immunogenetics, Research Program Immunology and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany. Electronic address: p.krammer@dkfz-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH